Company: IXHL
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001213900-25-092837
Chunk: 317

Company: Incannex Healthcare Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1A
Chunk 317
---
 business and results of operations may be adversely affected.

Some legal principles remain unresolved and there
has not been a consistent policy regarding the breadth or interpretation of claims allowed in patents in the United States, the United
Kingdom, the European Union, Australia or elsewhere. In addition, the specific content of patents and patent applications that are necessary
to support and interpret patent claims is highly uncertain due to the complex nature of the relevant legal, scientific and factual issues.
Changes in either patent laws or in interpretations of patent laws in Australia, the United States, the United Kingdom, the European Union
or elsewhere may diminish the value of our intellectual property or narrow the scope of our patent protection. Even if we are able to
obtain patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with
us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar
or alternative technologies or products in a non-infringing manner and export infringing products to territories where we do not have
patent protection, or to territories where we have patent protection, but where enforcement is not as strong as that in the United States.
These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient
to prevent them from competing. We may also fail to take the required actions or pay the necessary fees to maintain our patents.

Moreover, any of our pending applications may be
subject to a third-party pre-issuance submission of prior art to the USPTO, the European Patent Office (“EPO”), the Intellectual
Property Office, in the United Kingdom, the Australian Patent and Trademark Office and/or any patents issuing thereon may become involved
in opposition, derivation, reexamination, post grant review, interference proceedings or other patent office proceedings, inter partes
review or litigation, in the United States or elsewhere, challenging our patent rights. An adverse determination in any such submission,
proceeding or litigation could reduce the scope of, or invalidate, our patent rights, and allow third parties to commercialize our technology
or products and compete directly with us, without payment to us. In addition, if the breadth or strength of protection provided by our
patents and patent applications is threatened, it could dissuade companies from collaborating with us to exploit our intellectual property
or develop and commercialize drug candidates.

70

The issuance of a patent is not conclusive as to
the inventorship